ADB-CHMINACA

http://dbpedia.org/resource/ADB-CHMINACA an entity of type: Thing

ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015. rdf:langString

rdfs:label

rdf:langString ADB-CHMINACA

dbpedia-owl:wikiPageID

xsd:integer 46992168

dbpedia-owl:wikiPageRevisionID

xsd:integer 1082421316

dbpprop:c

xsd:integer 21

dbpprop:casNumber

xsd:integer 1185887

dbpprop:chemspiderid

xsd:integer 48059556

dbpprop:h

xsd:integer 30

dbpprop:iupacName

rdf:langString N-[-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-indazole-3-carboxamide

dbpprop:legalDe

rdf:langString Anlage II

dbpprop:legalStatus

rdf:langString Illegal in Singapore, Sweden, Switzerland

dbpprop:legalUk

rdf:langString Class B

dbpprop:legalUs

rdf:langString Schedule I

dbpprop:n

xsd:integer 4

dbpprop:o

xsd:integer 2

dbpprop:pubchem

xsd:integer 68894304

dbpprop:smiles

rdf:langString CC[C@H]C=O

dbpprop:stdinchi

xsd:integer 1

dbpprop:stdinchikey

rdf:langString ZWCCSIUBHCZKOY-GOSISDBHSA-N

dbpprop:unii

rdf:langString SL4C60689M

dbpedia-owl:abstract

rdf:langString ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015.

dbpprop:legalCa

rdf:langString Schedule II

dbpedia-owl:wikiPageLength

xsd:nonNegativeInteger 8244

dbpedia-owl:casNumber

xsd:string 1185887-13-1

dbpedia-owl:fdaUniiCode

xsd:string SL4C60689M

dbpedia-owl:pubchem

xsd:string 68894304

rdf:type

owl:Thing